Showing results (201-210 of 225) with videos related to
Sort By:
Pageof 23
Cell Death & Disease|May 8, 2015
ErbB2-intronic microRNA-4728: a novel tumor suppressor and antagonist of oncogenic MAPK signalingD C Schmitt, L Madeira da Silva, W Zhang, et al.Biomaterials|August 25, 2011
Enhanced osseointegration of titanium implant through the local delivery of transcription factor SATB2S G Yan, J Zhang, Q S Tu, et al.Schmerz (Berlin, Germany)|January 25, 2015
[Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain]W Häuser, F Bock, P Engeser, et al.Microbiology Spectrum|May 4, 2023
Full Profiling of GE81112A, an Underexplored Tetrapeptide Antibiotic with Activity against Gram-Negative PathogensSören M M Schuler, Gerrit Jürjens, Alexander Marker, et al.British Journal of Cancer|July 28, 2012
βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancerD C Christoph, S Kasper, T C Gauler, et al.Journal of Cancer Research and Clinical Oncology|July 19, 2023
Impact of encorafenib on survival of patients with BRAFV600E-mutant metastatic colorectal cancer in a real-world settingM Zurloh, M Goetz, T Herold, et al.Journal of Cancer Research and Clinical Oncology|July 13, 2022
The OUTREACH study: oncologists of German university hospitals in rotation on a palliative care unit-evaluation of attitude and competence in palliative care and hospiceT Biersching, A Schweda, K Oechsle, et al.Lung Cancer (Amsterdam, Netherlands)|February 25, 2015
HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomasH Reis, T Herold, S Ting, et al.ESMO Open|August 21, 2022
Multimodal survival prediction in advanced pancreatic cancer using machine learningJ Keyl, S Kasper, M Wiesweg, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2021
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaU Sahin, Ö Türeci, G Manikhas, et al.Pageof 23